FDA guidance for ABSSSI trials: Implications for conducting and interpreting clinical trials

Clinical Infectious Diseases

Volumn 58, Issue SUPPL. 1, 2014, Pages

  Itani, Kamal M F ^a   Shorr, Andrew F ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; C REACTIVE PROTEIN; PROCALCITONIN; SULFAMIDOCHRYSOIDINE; SULFANILAMIDE;

ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION; ARTICLE; BACTERIAL SKIN DISEASE; BURN INFECTION; CELLULITIS; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); CONCEPTUAL FRAMEWORK; DRUG EFFICACY; DRUG INDUSTRY; DRUG TISSUE LEVEL; ERYSIPELAS; ERYTHROCYTE SEDIMENTATION RATE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PERSONNEL; HUMAN; LEUKOCYTOSIS; OUTCOME ASSESSMENT; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SKIN ABSCESS; SKIN DEFECT; TREATMENT RESPONSE; ULTRAVIOLET RADIATION; WOUND INFECTION;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; ENDPOINT DETERMINATION; GUIDELINES AS TOPIC; HUMANS; PATIENT SELECTION; SKIN DISEASES, BACTERIAL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84892146223     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit612     Document Type: Article

References (23)

1. US Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry. Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment. Draft Guidance [monograph]. 2010. Clinical/antimicrobial revision 1. Available at: Http:// www.fda.gov/downloads/ Drugs/.../Guidances/ucm071185.pdf. Accessed 28 June 2013
2. Corey GR, Stryjewski ME. New rules for clinical trials of patients with acute bacterial skin and skin-structure infections: Do not let the perfect be the enemy of the good. Clin Infect Dis 2011; 52(Suppl 7):S469-76
3. US Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry. Uncomplicated and Complicated Skin and Skin Structure Infections - Developing Drugs for Treatment. Draft Guidance [monograph]. 1998. Available at: Http://www.fda.gov/ ohrms/dockets/98fr/2566dft.pdf. Accessed 28 June 2013
4. Talbot GH, Powers JH, Fleming TR, Siuciak JA, Bradley J, Boucher H; on behalf of the CABP-ABSSSI Project Team. Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: Update from the Biomarkers Consortium of the Foundation for the National Institutes of Health. Clin Infect Dis 2012; 55:1114-21
5. Rex JH. Development of drugs for skin infections. European Federation of Pharmaceutical Industries and Associations. http://www.ema.europa. eu/docs/en GB/document library/Presentation/2011/04/ WC500105481.pdf. Accessed 6 June 2013
6. Snodgrass WR, Anderson T. Prontosil in the treatment of erysipelas: A controlled series of 312 cases. BMJ 1937; 2:101-4
7. Snodgrass WR, Anderson T. Sulfanilamide in the treatment of erysipelas: A controlled series of 270 cases. BMJ 1937; 2:1156-9
8. US Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry, non-inferiority clinical trials. Available at: Http://www.fda.gov/downloads/Drugs/GuidanceComplianceRe gulatoryInformation/ Guidances/UCM202140.pdf. Accessed 6 June 2013
9. Toerner G, Burke L, Komo S, Papadopoulos E. A collaborative model for endpoint development for acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia. Clin Infect Dis 2012; 55:1122-3
10. Schumi J, Wittes JT. Through the looking glass: Understanding noninferiority. Trials 2011; 12:106
11. Mascha EJ. Equivalence and noninferiority testing in anesthesiology research. Anesthesiology 2010; 113:779-81
12. Spellberg B, Talbot GH, Boucher HW, et al. Antimicrobial agents for complicated skin and skin-structure infections: Justification of noninferiority margins in the absence of placebo-controlled trials. Clin Infect Dis 2009; 49:383-91
13. Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: Phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010; 51:641-50
14. Prokocimer P, De Anda C, Fang E, Mehra P, Das A. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: The ESTABLISH-1 randomized trial. JAMA 2013; 309:559-69
15. Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 2008; 46: 1683-93
16. Giuliano C, Kale-Pradhan PB, Johnson LB. Early response of ceftaroline fosamil in the treatment of soft-tissue infections. Expert Rev Clin Pharmacol 2012; 5:509-12
17. Friedland HD, O'Neal T, Biek D, et al. CANVAS 1 and 2: Analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 2012; 56:2231-6
18. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41:1373-406
19. Bien P, De Anda C, Prokocimer P. Comparison of digital planimetry and ruler technique to measure ABSSSI lesion sizes from the ESTABLISH 1 study. Surg Infect (Larchmt) [In press].
20. Jenkins TC, Sabel AL, Sarcone EE, Price CS, Mehler PS, Burman WJ. Skin and soft-tissue infections requiring hospitalization at an academic medical center: Opportunities for antimicrobial stewardship. Clin Infect Dis 2010; 51:895-903
21. Fang E, De Anda C, Das A, Prokocimer P. Efficacy and safety results from the ESTABLISH-2 ABSSSI study comparing IV and oral tedizolid phosphate and linezolid. In: Presented at: 23rd European Congress of Clinical Microbiology and Infectious Diseases; 27-30 April 2013; Berlin, Germany. Poster LB 2964
22. De Anda C, Fang E, Green S, Mehra P, Das A, Prokocimer P. Comparison of investigator assessed and programmatic clinical outcomes of tedizolid phosphate vs. linezolid in a phase 3 study in patients with ABSSSI. In: Presented at: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 9-12 September, 2012; San Francisco, CA. Poster L1-1665
23. Spellberg B. End points in trials of treatments for skin infections. JAMA 2013; 309:2091-2